Pharmaceuticals

In collaboration with the National Institute for Health and Care Excellence (NICE) in England, we explore some alternative methodological approaches that build on the incremental cost-effectiveness ratio.

We explore how the principles of insurance can be applied to structure reimbursement models for novel antibiotics, and ultimately stimulate innovation while offering financial protection to payers.

A research report that evaluates alternative payment models that potentially could be instituted by healthcare payers and manufacturers to pay for high-cost curative disease therapies and prescription drugs.

The rapid uptake of genetic testing within the National Health Service (NHS) and current debate around genetics make evaluating tailored interventions increasingly more relevant to ensure an efficient use of NHS spend.

The National Institute for Health and Clinical Excellence in England offers an interesting model for healthcare reform. We asked Joanne Buckle for her perspective.